ENvue Medical Inc.(FEED)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FEED

11/13/2026: FEED (1-star) is currently NOT-A-BUY. Pass it for now.

ENvue Medical Inc. is a micro-cap medical technology company specializing in non-invasive acoustic devices like UroShield and PainShield designed to prevent catheter biofilm and manage pain. The company's primary strength lies in its proprietary therapeutic technology and expanding international distribution footprint. Its main growth opportunity centers on scaling adoption within clinical and homecare settings and commercializing enteral care navigation platforms. However, significant risks include persistent net operating losses, tight liquidity, and intense competition from well-capitalized medical device conglomerates. The stock suits high-risk speculators or momentum investors, while market participants should closely monitor cash burn rates and international distribution milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitRevenue growth has stagnated despite innovative underlying medical technologies.
Momentum investorStrong fit while signal remains positiveLow share price and micro-cap status can trigger sharp short-term technical rallies.
Value investorWeak fitPersistent net losses and negative earnings make traditional value metrics unfavorable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for survival and growth.
Low-risk investorWeak fitHigh share price volatility and micro-cap risk profile present substantial capital loss exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading liquidity and micro-cap valuation cause extreme daily percentage price swings.
Valuation riskHighAbsence of net profitability makes standard price-to-earnings evaluations inapplicable.
Competition risk (large medical device conglomerates)HighMajor healthcare companies dominate hospital procurement channels, limiting market penetration.
Business qualityMedium / highWhile technology is specialized, ongoing financial losses weigh heavily on institutional quality metrics.
Dividend incomeLow / noneNo cash distribution is provided to shareholders.
Execution riskHighSuccess relies entirely on scaling distribution agreements and managing limited cash reserves.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.35M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 16.8K shares
Beta 1.58
52 Weeks Range 0.12 - 73.08
Updated Date 11/15/2026
52 Weeks Range 0.12 - 73.08
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -339.36

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -57.93%
Avg. Invested days 9
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FEED receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft analyst coverage.

Company Fundamentals

★★★★★
FEED has soft overall fundamentals (2 stars), with weak financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-390.8%), weak cash generation (FCF margin -369.4%), slightly negative revenue growth (-0.2%).

Financial Health Rating

★★★★★
FEED's financial health is weak, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets 1.5%). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
FEED's growth profile is soft, with the least-weak measure being revenue growth at -0.2% FY2025 versus FY2024. By comparison, while earnings growth (-390.8%, negative) and free-cash-flow growth (-274.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.0% and approximately 93.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.41% supports management-shareholder alignment.

Top 5 Institutional Investors

HRT FINANCIAL LLC 1.04%
Virtu Financial LLC 0.86%
Jane Street Group LLC 0.34%
Geode Capital Management, LLC 0.14%
TWO SIGMA SECURITIES, LLC 0.09%

Unit Economics (Per $1K Revenue)

★★★★★
FEED generates approximately $60 of gross profit, $-4,597 of operating income, and $-3,694 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 1.66%

Quantitative Style Profile

★★★★★
FEED has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Urology and Catheter Care DevicesSales of UroShield systems, consumable accessories, and related replacement components to hospitals and homecare providers.This is the primary revenue driver, though total sales volumes remain relatively small.
Pain Therapy and Therapeutic DevicesCommercialization of PainShield units for clinical and at-home pain management applications.Serves as a secondary product line contributing supplementary revenue.
International and Domestic DistributionDirect-to-consumer sales channels and international partnerships across Europe, Israel, and Australia.Geographic expansion relies heavily on third-party distributors rather than direct enterprise scale.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 575.16K
Price to Sales(TTM) 0.18
Enterprise Value 575.16K
Price to Sales(TTM) 0.18
Enterprise Value to Revenue 0.3
Enterprise Value to EBITDA 0.43
Shares Outstanding 923.72K
Shares Floating 859.21K
Shares Outstanding 923.72K
Shares Floating 859.21K
Percent Insiders 16.41
Percent Institutions 1.03

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.